Overview

An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence

Status:
Unknown status

Trial end date:
2018-12-01

Target enrollment:

Participant gender:

Summary

The primary objective is to determine the dose dependent effects of treatment with perindopril on methamphetamine (MA)-induced craving and on the reinforcing effects of MA indexed by MA self-administration. We will also determine the effects of treatment with candesartan on MA-induced craving and on the reinforcing effects of MA indexed by MA self-administration.

Phase:

Phase 1

Details

Lead Sponsor:

Baylor College of Medicine

Collaborator:

National Institute on Drug Abuse (NIDA)

Treatments:

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Candesartan
Candesartan cilexetil
Methamphetamine
Perindopril